11
Views
7
CrossRef citations to date
0
Altmetric
Original Article

C1-Inhibitor and Its Genetic Alterations in Hereditary Angioneurotic Edema

Pages 1-16 | Received 06 May 1992, Published online: 10 Jul 2009

References

  • Lepow I. H., Ratnoff O. D., Rosen F. S., Pillemer L. Observations on a proesterase associated with partially purified first component of human complement (C'1). Proc. Soc. Exp. Biol. Med. 1956; 92: 32–37
  • Ratnoff O. D., Lepow I. H. Some properties of an esterase derived from preparations of the first component of complement. J. Exp. Med. 1957; 106: 327–343
  • Lepow I. H., Ratnoff O. D., Levy L. R. Studies on the activation of a proesterase associated with partially purified first component of human complement. J. Exp. Med. 1958; 107: 451–474
  • Levy L. R., Lepow I. H. Assay and properties of serum inhibitor of C'1 esterase. Proc. Soc. Exp. Biol. Med. 1959; 101: 608–611
  • Pensky J., Levy L. R., Lepow I. H. Partial purification of a serum inhibitor of C'1 esterase. J. Biol. Chem. 1961; 236: 1674–1679
  • Schultze H. E., Heide K., Haupt H. Uber ein bisher unbekanntes saures alpha-2 glykoprotein. Naturwissenschafien 1962; 49: 133–134
  • Pensky J., Schwick H. G. Human serum inhibitor of C'1-esterase: identity with alpha 2-neura-minoglycoprotein. Science 1967; 163: 698–699
  • Haupt H., Heimburger N., Kranz T., Schwick H. G. Ein Beitrag zur Isolierung und Charakterisierung des C1-Inaktivators aus Humanpiasma. Eur. J. Biochem. 1970; 17: 254–261
  • Donaldson V. H. Studies on the activation of a serum esterase with ether and its relationship to C'1 esterase. J. Clin. Invest. 1961; 40: 673–683
  • Donaldson V. H., Evans R. R. Absence of an enzyme inhibitor in hereditary angioneurotic edema. J. Lab. Clin. Med. 1961; 58: 812
  • Donaldson V. H., Evans R. R. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor in C'1-esterase. Am. J. Med. 1963; 35: 37–44
  • Ziccardi R. J. A new role for C1-inhibitor in hemostasis: control of activation of the first component of human complement. J. Immunol. 1982; 128: 2505–2508
  • Ziccardi R. J. Spontaneous activation of the first component of human complement (C1) by an intramolecular autocatalytic mechanism. J. Immunol. 1982; 128: 2500–2504
  • Haines A. L., Lepow I. H. Studies on human C'1 esterase. I. Purification and enzymatic properties. J. Immunol. 1964; 92: 456–467
  • Donaldson V. H., Rosen F. S. Action of complement in hereditary angioneurotic edema: the role of C'1-esterase. J. Clin. Invest. 1964; 45: 2204–2213
  • Forbes C. D., Pensky J., Ratnoff O. D. Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum C1 inactivator. J. Lab. Clin. Med. 1970; 76: 809–815
  • Ratnoff O. D., Pensky J., Ogston D., Naff G. B. The inhibition of plasmin, plasma kallikrein, plasma permeability factor and the C1r subcomponent of the first component of complement by serum C1 esterase inhibitor. J. Exp. Med. 1969; 129: 315–331
  • Booth N. A., Walker E., Maughan R., Bennett B. Plasminogen activator in normal subjects after exercise and venous occlusion: tPA circulates as complexes with C1 inhibitor and PAI-1. Blood 1987; 69: 1600–1604
  • Bennett B., Croll A., Ferguson K., Booth N. A. Complexing of tissue plasminogen activator with PAI-1, alpha 2-macroglobulin, and C1-inhibitor: studies in patients with defibrination and a fibrinolytic state after electroshock or complicated labor. Blood 1990; 75: 671–676
  • Faulmann E. L., Young M., Boyle M. D. P. Inactivation of the proteolytic activity of mouse nerve growth factor by human C1-inhibitor. J. Immunol. 1987; 138: 4336–4340
  • Green L. A., Shooter E. M., Varon S. Subunit interaction and enzymatic activity of mouse 7S nerve growth factor. Biochemistry 1969; 8: 3735–3741
  • Dunbar J. C., Bradshaw R. A. Nerve growth factor biosynthesis: isolation and characterization of a guinea pig prostate kallikrein. J. Cell. Biochem. 1985; 29: 309–319
  • Bock S. C., Skriver K., Nielsen E., Thørgeson H-C., Wiman B., Donaldson V. H., Eddy R. L., Marrinan J., Radziejewska E., Huber R., Shows T. B., Magnusson S. Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry 1986; 25: 4292–4301
  • Davis A. E., III. C1 inhibitor and hereditary angioneurotic edema. Annu. Rev. Immunol. 1988; 6: 595–628
  • Salvesen G. S., Catanese J. J., Kress L. E., Travis J. Primary structure of the reactive site of human C1-inhibitor. J. Biol. Chem. 1985; 260: 2432–2436
  • Johnson A. M., Alper C. A., Rosen F. S., Craig J. M. C1-inhibitor: Evidence for decreased hepatic synthesis in hereditary angioneurotic edema. Science 1971; 173: 553–554
  • Bensa J. C., Reboul A., Colomb M. G. Biosynthesis in vitro of complement subcomponents C1q, C1s and C1-inhibitor by resting and stimulated human monocytes. Biochem. J. 1983; 216: 385–392
  • Katz Y., Strunk R. C. Synthesis and regulation of C1 inhibitor in human skin fibroblasts. J. Immunol. 1989; 142: 2041–2045
  • Randazzo B. P., Dattwyler R. J., Kaplan A. R., Ghebrehiwet B. Synthesis of C1 inhibitor (C1-INA) by a human monocyte-like cell line, U-937. J. Immunol. 1985; 135: 1313–1319
  • Morris K. M., Aden D. E., Knowles B. B., Colton H. R. Complement biosynthesis by the human hepatoma-derived cell line HepG2. J. Clin. Invest. 1982; 70: 906–913
  • Prandini M. H., Reboul A., Colomb M. G. Biosynthesis of complement C1 inhibitor by Hep G2 cells. Reactivity of different glycosylated forms of the inhibitor with C1s. Biochem. J. 1986; 237: 93–98
  • Lotz M., Zuraw B. L. Interferon-gamma is a major regulator of C1-inhibitor synthesis by human blood monocytes. J. Immunol. 1987; 139: 3382–3387
  • Donaldson V. H., Olivi L., Radziejewska E., Bock S. C., Wagner C. J. Human umbilical endothelial cells produce C1-inhibitor mRNA and secrete C1-inhibitor. Behring Inst. Mitt. 1989; 84: 194
  • Schmaier A. H., Murray S. C., Heda G. D., Farber A., Kuo A., McCrae K., Cines D. B. Synthesis and expression of C1 inhibitor by human umbilical vein endothelial cells. J. Biol. Chem. 1989; 264: 18173–18179
  • Reboul A., Prandini M. H., Colomb M. G. Proteolysis and deglycosylation of human C1 inhibitor. Effect on functional properties. Biochem. J. 1987; 244: 117–121
  • Minta J. O. The role of sialic acid in the functional activity and the hepatic clearance of C1-INH. J. Immunol. 1981; 126: 245–249
  • Lepow I. H., Naff G. B., Todd E. W., Pensky J., Hinz C. F., Jr. Chromatographic resolution of the first component of human complement into three activities. J. Exp. Med. 1963; 117: 983–1008
  • Naff G. B., Ratnoff O. D. The enzymatic nature of C1r. Conversion of C1s to C'1 esterase and digestion of amino acid esters by C1r. J. Exp. Med. 1968; 128: 571–593
  • Sim R. B., Reboul A., Arlaud G. J., Villiers C. L., Colomb M. G. Interaction of 125-labelled complement subcomponents C1r and C1s with protease inhibitors in plasma. FEBSLett. 1979; 97: 111–115
  • Ziccardi R. J. The role of immune complexes in the activation of the first component of human complement. J. Immunol. 1984; 132: 283–288
  • Laurell A-B., Johnson U., Mårtensson U., Sjöholm A. G. Formation of complexes composed of C1r, C1s, and C1-inactivator in human serum on activation of C1. Acta Pathol. Microbiol. Scand. 1978; 86: 299–306
  • Ziccardi R. J., Cooper N. R. Active disassembly of the first component of complement, C-1 by C-1 inactivator. J. Immunol. 1979; 123: 788–792
  • Laurell A-B., Mårtensson U., Sjöholm A. G. C1 subcomponent complexes in normal and pathological sera studied by crossed immunoelectrophoresis. Acta Pathol. Microbiol. Scand. 1976; 84: 455–464
  • Donaldson V. H. C'1 activation in hereditary angioneurotic edema plasma: role of urokinase and inhibitors. J. Appl. Physiol. 1968; 25: 416–424
  • Donaldson V. H. Mechanisms of activation of C'1 esterase in hereditary angioneurotic edema plasma in vitro. The role of Hageman factor, a clot-promoting agent. J. Exp. Med. 1968; 127: 411–429
  • Ziccardi R. J. A. new role for C1-inhibitor in homeostasis: control of activation of the first component of human complement. J. Immunol. 1982; 128: 2505–2508
  • Tenner A. J., Frank M. M. Activator-bound C1 is less susceptible to inactivation by C1 inhibition that is fluid phase C1. J. Immunol. 1986; 137: 625–630
  • Gigli I., Mason J. W., Colman R. W., Austen K. F. Interaction of plasma kallikrein with the C1-inhibitor. J. Immunol. 1970; 104: 574–581
  • Harpel P. C., Cooper N. R. Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interactions with C1s, plasmin and trypsin. J. Clin. Invest. 1975; 55: 593–604
  • Aoki N., Moroi M., Matsuda M, Tachiya K. The behavior of alpha 2-plasmin inhibitor in fibrinolytic states. J. Clin. Invest. 1977; 60: 361–369
  • Harpel P. C. Alpha 2-plasmin inhibitor and alpha 2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay. J. Clin. Invest. 1981; 68: 46–55
  • Weiss V., Engel J. Heparin-stimulated modification of C1-inhibitor by subcomponent C1s of human complement. Hoppe Seylers Z. Physiol. Chem. 1983; 364: 295–301
  • Chesne S., Villiers C. L., Arlaud G. J., LaCroix M. B., Colomb M. G. Fluid-phase interaction of C1-inhibitor (C1-INH) and the subcomponents C1r and C1s of the first component of complement, C1. Biochem. J. 1982; 201: 61–70
  • Patston P. A., Gettins R., Beechem J., Schapira M. Mechanism of serpin action: Evidence that C1 inhibitor functions as a suicide substrate. Biochemistry 1991; 30: 8876–8882
  • Schapira M., Scott C. F., Colman R. W. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J. Clin. Invest. 1982; 69: 462–468
  • Van der Graff F., Koedam J. A., Bouma B. N. Inactivation of kallikrein in human plasma. J. Clin. Invest. 1983; 71: 149–158
  • Lewin M. F., Kaplan A. P., Harpel P. C. Studies of C1-inactivator-plasma kallikrein complexes in purified systems and in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay. J. Biol. Chem. 1983; 258: 6415–6421
  • Harpel P. C., Lewin M. F., Kaplan A. P. Distribution of plasma kallikrein between C1 inactivator and alpha 2-macroglobulin in plasma utilizing a new assay for alpha 2-macroglobulin-kallikrein complexes. J. Biol. Chem. 1985; 260: 4257–4263
  • De Agostini A., Lijnen H. R., Pixley R. A., Colman R. W., Schapira M. Inactivation of factor XII active fragment in normal plasma. Predominant role of C1-inhibitor. J. Clin. Invest. 1984; 73: 1542–1549
  • Pixley R. A., Schapira M., Colman R. W. The regulation of human factor XIIa by plasma proteinase inhibitors. J. Biol. Chem. 1985; 260: 1723–1729
  • Wachtfogel Y. T., Harpel P. C., Edmunds L. H., Jr, Colman R. W. Formation of Cls-Cl-inhibitor, kallikrein-Cl-inhibitor, and plasmin-alpha 2-plasmin-inhibitor complexes during cardiopulmonary bypass. Blood 1989; 73: 468–471
  • Kaufman N., Page J. D., Pixley R. A., Schein R., Schmaier A. H., Colman R. W. Alpha 2-macroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis. Blood 1991; 77: 2660–2667
  • Nuijens J. H., Huijbregts C. M., Eerenberg-Belmer A. J. M., Abbink J. J., Strack van Schijndel R. J. M., Felt-Bersma R. J. K., Thijs L. G., Hack C. E. Quantification of plasma factor XIIa-C1-inhibitor and kallikrein-C1-inhibitor complexes in sepsis. Blood 1988; 72: 1841–1848
  • Donaldson V. H., Rosen F. S. Hereditary angioneurotic edema: a clinical survey. Pediatrics 1966; 37: 1017–1027
  • Donaldson V. H., Ratnoff O. D., Dias Da Silva W., Rosen F. S. Permeability-increasing activity in hereditary angioneurotic edema plasma. J. Clin. Invest. 1969; 48: 642–653
  • Klemperer M. R., Donaldson V. H., Rosen F. S. Effect of C'1 esterase on vascular permeability in man: Studies in normal and complement-deficient individuals and in patients with hereditary angioneurotic edema. J. Clin. Invest. 1968; 47: 604–611
  • Strang C. J., Auerback H. S., Rosen F. S. C1s-induced vascular permeability in C2-deficient guinea pigs. J. Immunol. 1986; 137: 631–635
  • Donaldson V. H., Rosen F. S., Bing D. H. Role of the second component of complement (C2) and plasmin in kinin release in hereditary angioneurotic edema (H.A.N.E.) plasma. Trans. Assoc. Am. Physicians 1977; 90: 174–183
  • Fields T., Ghebrehiwet B., Kaplan A. P. Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of “spontaneous” formation of bradykinin. J. Allergy Clin. Immunol. 1983; 72: 54–60
  • Schapira M., Silver L. D., Scott C. E., Schmaier A. H., Prograis L. J., Jr, Curd J. G., Colman R. W. Prekallikrein activation and high-molecular-weight-kininogen consumption in hereditary angioedema. N. Engl. J. Med. 1983; 308: 1050–1053
  • Landerman N. S., Webster M. E., Becker E. L., Ratcliffe H. E. Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J. Allergy 1962; 33: 330–341
  • Rosen F. S., Charache P., Pensky J., Donaldson V. H. Hereditary angioneurotic edema: two genetic variants. Science 1965; 148: 957–958
  • Rosen F. S., Alper C. A., Pensky J., Klemperer M. R., Donaldson V. H. Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema. J. Clin. Invet. 1971; 50: 2143–2149
  • Quincke H. über akutes umschreibenes Hautodem, Monatschefte fur praktische. Dermatology 1882; 1: 129–131
  • Osier W. Hereditary angio-neurotic oedema. Am. J. Med. Sci. 1888; 95: 362–367
  • Donaldson V. H., Harrison R. A., Rosen F. S., Bing D. H., Kindness G., Canar J., Wagner C. J., Awad S. Variability in purified dysfunctional C1-inhibitor proteins from patients with hereditary angioneurotic edema. J. Clin. Invest. 1985; 75: 124–132
  • Donaldson V. H., Wagner C. J., Tsuei B., Kindness G., Bing D. H., Harrison R. A., Rosen F. S. Interactions of plasma kallikrein and C1s with normal and dysfunctional C1-inhibitor proteins from patients with hereditary angioneurotic edema: Analytic gel studies. Blood 1987; 69: 1096–1011
  • Donaldson V. H., Mitchell B. H., Everson B., Ratnoff O. D. Interactions of C1-inhibitors from normal persons and patients with Type II hereditary angioneurotic edema with purified activated Hageman factor (factor XIIa). Blood 1990; 75: 911–921
  • Quastel M., Harrison R., Cicardi M., Alper C. A., Rosen F. S. Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema. J. Clin. Invest. 1983; 71: 1041–1046
  • Lachmann P. J., Rosen E. S. The catabolism of C1 inhibitor and the pathogenesis of hereditary angioedema. Acta Pathol. Microbiol. Immunol. Scand. Suppl 1984; 284: 35–39
  • Woo R., Lachmann P. J., Harrison R. A., Amos N., Cooper C., Rosen F. S. Simultaneous turnover of normal and dysfunctional C1 inhibitor as a probe of in vivo activation of C1 and contact activated proteases. Clin. Exp. Immunol. 1985; 61: 1–8
  • Cugno M., Nuijens J., Hack E., Eerenberg A., Frangi D., Agostoni A., Cicardi M. Plasma levels of C1-inhibitor complexes and cleaved C1-inhibitor in patients with hereditary angioneurotic edema. J. Clin. Invest. 1990; 85: 1215–1220
  • Kramer J., Katz Y., Rosen F. S., Davis A. E., III, Strunk R. C. Synthesis of C1 inhibitor in fibroblasts from patients with type I and type II hereditary angioneurotic edema. J. Clin. Invest. 1991; 87: 1614–1620
  • Cicardi M., Igarashi T., Rosen F. S., Davis A. E., III. Molecular basis for the deficiency of complement 1 inhibitor in type I hereditary angioneurotic edema. J. Clin. Invest. 1987; 79: 698–702
  • Lappin D. E., McPhaden A. R., Yap P. L., Carter P. E., Birnie G. D., Fothergill J. E., Whaley K. Monocyte C1-inhibitor synthesis in patients with C1-inhibitor deficiency. Eur. J. Clin. Invest. 1989; 19: 45–52
  • Que B. G., Petra P. H. Isolation and analysis of a cDNA coding for human C1-inhibitor. Biochem. Biophys. Res. Commun. 1986; 137: 620–625
  • Davis A. E., III, Whitehead A. S., Harrison R. A., Dauphinais A., Bruns G. A. R., Cicardi M., Rosen E. S. Human inhibitor of the first component of complement, C1: Characterization of cDNA clones and localization of the gene to chromosome 11. Proc. Natl. Acad. Sci. USA 1986; 83: 3161–3165
  • Davis A. E., III. Hereditary and acquired deficiencies of C1-inhibitor. Immunodefic. Rev. 1989; 1: 207–226
  • Carter P. E., Duponchel C., Tosi M., Fothergill J. E. Complete nucleotide sequence of the gene for human C1-inhibitor with an unusually high density of Alu elements. Eur. J. Biochem. 1991; 197: 301–308
  • Stoppa-Lyonnet D., Tosi M., Laurent J., Sobel A., Lagrue G., Meo T. Altered C1 inhibitor genes in type I hereditary angioneurotic edema. N. Engl. J. Med. 1987; 317: 1–6
  • Tosi M., Stoppa-Lyonnet D., Carter P., Meo T. Molecular defects of the C1-inhibitor gene in hereditary angioedema. Behring Inst. Mitt. 1989; 84: 173–179
  • Stoppa-Lyonnet D., Duponchel C., Meo T., Laurent J., Carter P. E., Arala-Chavez M., Cohen J. H. M., Dewald G., Goetz J., Hauptmann G., Lagrue G., Lesavre R., Lopaz-Trascasa M., Mistano G., Moraine C., Sobel A., Spath P. J., Tosi M. Recombinational biases in the rearranged C1-inhibitor genes of hereditary angioedema patients. Am. J. Hum. Genet. 1991; 49: 1055–1062
  • Carter P. E., Dunbar B., Fothergill J. E. Genomic cDNA cloning of the human C1 inhibitor. Intronexon junctions and comparison with other serpins. Eur. J. Biochem. 1988; 173: 163–169
  • Cicardi M., Igarashi T., Kim M. S., Frangi D., Agostoni A., Davis A. E., III. Restriction fragment length polymorphism of the C1 inhibitor gene in hereditary angioneurotic edema. J. Clin. Invest. 1987; 80: 1640–1643
  • Ariga T., Carter P. E., Davis A. E., III. Recombinations between Alu repeat sequences that result in partial deletions within the C1-inhibitor gene. Genomics 1990; 8: 607–613
  • Stoppa-Lyonnet D., Carter P. E., Meo T., Tosi M. Clusters of intragenic Alu repeats predispose the human C1 inhibitor locus to deleterious rearrangements. Proc. Natl. Acad. Sci. USA 1990; 87: 1551–1555
  • McPhaden A. R., Birnie G. D., Whaley K. Restriction fragment length polymorphism analysis of the C1-inhibitor gene in hereditary C1-inhibitor deficiency. Clin. Genet. 1991; 39: 161–171
  • Jelinek W. R., Schmid C. W. Repetitive sequences in eukaryotic DNA and their expression. Annu. Rev. Biochem. 1982; 51: 813–844
  • Ullu E., Tschudi C. Alu sequences are processed 7SL RNA genes. Nature 1984; 312: 171–172
  • Davis A. E., III, Bissler J. J., Aulak K. S. Genetic defects in the C1 inhibitor gene. Complement Profiles 1992., In press.)
  • Bissler J. J., Donaldson V. H., Cicardi M., Davis A. E., III. Intra-exonic deletions and insertions in the C1 inhibitor gene. FASEB J. 1992; 6: A1452, No. 4, (Abstract)
  • Ariga T., Igarashi T., Ramesh N., Parad R., Cicardi M., Davis A. E., III. Type I C1 inhibitor deficiency with a small messenger RNA resulting from deletion of one exon. J. Clin. Invest. 1989; 83: 1888–1893
  • Verpy E., Laurent J., Spath P. J., Meo T., Tosi M. Clustering of point mutations downstream of the C1-inhibitor reactive site in hereditary angioedema patients. Complement Inflamm. 1991; 8: 296, (Abstract)
  • Siddique Z. M., McPhaden A. R., Whaley K. A frameshift mutation giving rise to a premature stop codon in exon 8 of the C1-inhibitor gene of a Type I HAE patient. Clin. Exp. Immunol. 1991; 86: 11, (Abstract)
  • Frangi D., Cicardi M., Sica A., Colotta E., Agostoni A., Davis A. E., III. Nonsense mutations affect C1-inhibitor messenger RNA levels in patients with type I hereditary angioneurotic edema. J. Clin. Invest. 1991; 88: 755–759
  • Aulak K. S., Cicardi M., Harrison R. A. Identification of a new PI residue mutation (444 ARG←Ser) in a dysfunctional C1-inhibitor protein contained in a type II hereditary angioedema plasma. Febs Lett. 1990; 266: 13–16
  • Donaldson V. H., Bissler J. J. C1-inhibitors and their genes: An update. J. Lab. Clin. Med. 1992; 119: 330–333
  • Skriver K., Radziejewska E., Silbermann J. A., Donaldson V. H., Bock S. C. CpG mutations in the reactive site of human C1 inhibitor. J. Biol. Chem. 1989; 264: 3066–3071
  • Cooper D. N., Youssoufian H. The CpG dinucleotide and human genetic disease. Hum. Genet. 1988; 78: 151–155
  • Frangi D., Aulak K. S., Cicardi M., Harrison R. A., Davis A. E., III. A dysfunctional C1 inhibitor protein with a new reactive center mutation (ARG 444←Leu). Febs Lett. 1992; 301: 34–46
  • Parad R. B., Kramer J., Strunk R. C., Rosen F. S., Davis A. E., III. Dysfunctional C1 inhibitor Ta:deletion of Lys-251 results in acquisition of an N-glycosylation site. Proc. Natl. Acad. Sci. U. S. A. 1990; 88: 6786–6790
  • Skriver K., Wikoff W. R., Patston P. A., Tausk F., Schapira M., Kaplan A. P., Bock S. C. Substrate properties of C1 inhibitor Ma (Alanine 434←Glutamic acid). Genetic and structural evidence suggesting that the P12-region contains critical determinants of serine protease inhibitor inhibitor/substrate status. J. Biol. Chem. 1991; 266: 9216–9221
  • Levy N. J., Ramesh N., Cicardi M., Harrison R. A., Davis A. E., III. Type H hereditary angioneurotic edema that may result from a single nucleotide change in the codon for alanine-436 in the C1-inhibitor gene. Proc. Natl. Acad. Sci. USA 1990; 87: 265–268
  • Davis A. E., III, Aulak K. S., Parad R. B., Stecklein H. P., Eldering E., Hack C. E., Kramer J., Strunk R. C., Rosen F. S. Characterization and expression of C1-inhibitor non-reactive center mutations. Complement Inflamm. 1991; 8: 138, (Abstract)
  • Stead N., Kaplan A. R., Rosenberg R. D. Inhibition of activated factor XII by antithrombin-heparin cofactor. J. Biol. Chem. 1976; 251: 6481–6488
  • Saito H., Goldsmith G. H., Moroi M., Aoki N. Inhibitory spectrum of alpha 2-plasmin inhibitor. Proc. Natl. Acad. Sci. USA 1979; 76: 2013–2017
  • Harpel P. C. Human plasma alpha 2-macroglobulin. An inhibitor of plasma kallikrein. J. Exp. Med. 1970; 132: 329–352
  • Venneröd A. M., Laake K. Inhibition of purified plasma kallikrein by antithrombin III and heparin. Thromb. Res. 1975; 7: 223–226
  • Fritz H., Wunderer G., Kummer K., Heimburger N., Werle E. Alpha 1-antitrypsin und C1-inaktivator: Progressiv-inhibitoren für serumkallikreine von mensch und schwein. Hoppe Seylers Z. Physiol. Chem. 1972; 353: 906–910
  • McConnell D. J. Inhibitors of kallikrein in human plasma. J. Clin. Invest. 1972; 51: 1611–1623
  • Gans H., Tan B. H. Alpha 1-antitrypsin, an inhibitor for thrombin and plasmin. Clin. Chim. Acta 1967; 17: 111–117
  • Moroi M., Aoki N. Isolation and characterization of α2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J. Biol. Chem. 1976; 251: 5956–5965
  • Ganrot P. O. Interaction of plasmin and trypsin with alpha 2-macroglobulin. Acta Chem. Scand. 1967; 21: 602–608
  • Heck L. W., Kaplan A. R. Substrates of Hageman factor. I. Isolation and characterization of human factor XI (PTA) and inhibition of the activated enzyme by alpha 1-antitrypsin. J. Exp. Med. 1974; 140: 1615–1630
  • Skriver K., Wikoff W. R., Stoppa-Lyonnet D., Donaldson V. H., Bock S. C. 1992, Unpublished observations.
  • Cicardi M., Bergamaschini L., Marasini B., Boccassini G., Tucci A., Agostoni A. Hereditary angioedema: an appraisal of 104 cases. Am. J. Med. Sci. 1982; 284: 2–9
  • Bergamaschini L., Cicardi M., Tucci A., Gardinali M., Frangi D., Valle C., Agostoni A. C1 INH concentrate in the therapy of hereditary angioedema. Allergy 1983; 38: 81–84
  • Lundh B., Laurell A-B., Wetterqvist H., White T., Granerus G. A case of hereditary angioneurotic oedema, successfully treated with epsilon-aminocaproic acid. Studies on C'1 esterase inhibitor, C'1 activation, plasminogen level and histamine metabolism. Clin. Exp. Immunol. 1968; 3: 733–745
  • Frank M. M., Sergent J. S., Kane M. A., Ailing D. W. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N. Engl. J. Med. 1972; 286: 808–812
  • Marasini B., Cicardi M., Martignoni G. C., Agostoni A. Treatment of hereditary angioedema. Klin. Wochenschr. 1978; 56: 819–823
  • Sheffer A. L., Austen K. F., Rosen F. S. Tranexamic acid therapy in hereditary angioneurotic edema. N. Engl. J. Med. 1972; 287: 452–454
  • Sim T. C., Grant J. A. Hereditary angioedema: its diagnostic and management perspectives. Am. J. Med. 1990; 88: 656–664
  • Spaulding W. B. Methyltestosterone therapy for hereditary episodic edema (hereditary angioneurotic edema). Ann. Intern. Med. 1960; 53: 739–745
  • Gelfand J. A., Sherins R. J., Ailing D. W., Frank M. M. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N. Engl. J. Med. 1976; 295: 1444–1448
  • Hosea S. W., Santaella M. L., Brown E. J., Berger M., Katusha K., Frank M. M. Long-term therapy of hereditary angioedema with danazol. Ann. Intern. Med. 1980; 93: 809–812
  • Pitts J. S., Donaldson V. H., Forristal J., Wyatt R. J. Remissions induced in hereditary angioneurotic edema with an attenuated androgen (danazol): correlation between concentrations of C1-inhibitor and the fourth and second components of complement. J. Lab. Clin. Med. 1978; 92: 501–507
  • Donaldson V. H. Danazol. Am. J. Med. 1989; 87(3N): 49N–55, N
  • Bagheri S. A., Boyer J. L. Peliosis hepatis associated with androgenic-anabolic steroid therapy. A severe form of hepatic injury. Ann. Intern. Med. 1974; 81: 610–618

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.